Substance / Medication

Sorafenib tosylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Thyroid Arterial Embolization for the Management of Benign and Malignant Thyroid Disease: A Systematic Review.
Coerts Hannelore Iris, D'Mello Brooke, Verburg Frederik Anton et al. · Endocr Pract · 2026
PMID: 40780312Meta-Analysis
Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis.
Ning Kang, Chen Qiaorong, Guo Yu et al. · Int J Surg · 2026
PMID: 40865971Meta-AnalysisFull text (PMC)
Efficacy and Safety of Targeted Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer.
Zhang Yuqing, Zhang Xiaoxin, Lin Lifan et al. · J Clin Endocrinol Metab · 2025
PMID: 39292866Meta-Analysis
Associations Between Obesity and Risk of Thyroid Cancer: A Meta-Analysis of Cohort Studies.
Hisan Urfa Khairatun, Myung Seung-Kwon, Nguyen Giap Viet · Nutr Cancer · 2025
PMID: 39460502Meta-Analysis
Completion Thyroidectomy Trends and Rates: A Systematic Review and Meta-Analysis.
Soibelman Daniel, Ronen Ohad · Clin Otolaryngol · 2025
PMID: 39587912Meta-AnalysisFull text (PMC)
Association between metabolic dysfunction-associated steatotic liver disease and risk of thyroid cancer: a systematic review and meta-analysis.
Chen JiaHao, Gao YingZheng, Fu Tao et al. · Eur J Gastroenterol Hepatol · 2025
PMID: 39589817Meta-Analysis
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J, Hoyle M, Green C et al. · Health Technol Assess · 2010
PMID: 20028613Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sorafenib tosylate (substance)
SNOMED CT
432886002
UMLS CUI
C1676709

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Sorafenib tosylate: Uses, Evidence & Side Effects | Ltrl